Related Experiment Video
Updated: Aug 17, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
The immunobiology of malignant gliomas
1Department of Animal Biology, University of Pavia, Pavia, Italy. nano@unipv.it
Abstract:
In spite of continuing advances in surgery, radiotherapy and chemotherapy, the last few decades have brought little improvement in the prognosis of malignant brain tumours. New immunotherapeutic strategies are being studied in numerous laboratories throughout the world in an effort to gather the further clinical and biological data needed in order to render these therapies effective and selective. The authors review recent advances in understanding of the immunobiology of brain tumours, in particular malignant gliomas. The biological basis of the interaction between nervous system cells and cancer cells is still an unresolved question and a constantly evolving area of research. Particular attention is paid to interleukin-2, one of the few effective cytokines used in the adjuvant treatment of some tumours. However, there is still a long way to go before these and other immunological approaches can be considered really applicable in the treatment of malignant gliomas.
Insights
Immunotherapy offers new hope for malignant brain tumors, but more research is needed. Understanding the immune system
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Malignant brain tumors have a poor prognosis despite advances in conventional treatments.
- Immunotherapy is being explored as a novel treatment strategy.
- The interaction between the nervous and immune systems in brain tumors is complex and under investigation.
Purpose of the Study:
- To review recent advances in the immunobiology of brain tumors, focusing on malignant gliomas.
- To discuss the potential of immunotherapeutic strategies, including interleukin-2.
Main Methods:
- Literature review of recent research on brain tumor immunobiology.
- Analysis of the role of cytokines, such as interleukin-2, in cancer treatment.
Main Results:
- Significant progress has been made in understanding brain tumor immunobiology.
- Interleukin-2 shows promise as an adjuvant therapy for certain tumors.
- The biological basis of neuro-immune interactions in gliomas remains an active research area.
Conclusions:
- While immunotherapy holds potential for treating malignant gliomas, further research is essential.
- More clinical and biological data are needed to develop effective and selective immunotherapies.
- Current immunotherapeutic approaches are not yet widely applicable for malignant glioma treatment.
